Lumos Pharma — NewLink Genetics — Corporate Update (June 2017)
6 slides from Lumos Pharma's corporate update, Jun 8, 2017
Slide 1: NewLink Genetics Corporation June 8, 2017 Conference Call on GDC-0919 Program
NewLink Genetics Corporation Nasdaq: NLNK June 8, 2017 Conference Call on GDC-0919 Program
Slide 2: Forward-Looking Disclaimer
Zakharia Y, et al. Oral presentation at: 107th Annual Meeting of the American Association for Cancer Research (AACR); April 1-5, 2017; Washington, DC. Abstract CT117. Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that involve substantial risks and uncert
Slide 3: NewLink Participants and Agenda
Zakharia Y, et al. Oral presentation at: 107th Annual Meeting of the American Association for Cancer Research (AACR); April 1-5, 2017; Washington, DC. Abstract CT117. NewLink Participants and Agenda 3 Introduction Jack Henneman, Executive Vice President & CFO GDC-0919 Decision Review Charles J.
Slide 4: Indoximod plus Pembrolizumab (PD-1): Best Response by RECIST Criteria
Zakharia Y, et al. Oral presentation at: 107th Annual Meeting of the American Association for Cancer Research (AACR); April 1-5, 2017; Washington, DC. Abstract CT117. Indoximod plus Pembrolizumab (PD-1) 4 Best Response by RECIST Criteria n (%) n = 51 † Overall Response Rate 30 (59) Complete Response
Slide 5: Indoximod plus Pembrolizumab (PD-1): Clinical Benefit and Disease Control Rate
Zakharia Y, et al. Oral presentation at: 107th Annual Meeting of the American Association for Cancer Research (AACR); April 1-5, 2017; Washington, DC. Abstract CT117. Indoximod plus Pembrolizumab (PD-1) 5 Impressive Clinical Benefit and Disease Control Rate *SD of primary lesion; new non-target lesi
Slide 6: Indoximod plus Provenge (sipuleucel-T) Vaccine
Zakharia Y, et al. Oral presentation at: 107th Annual Meeting of the American Association for Cancer Research (AACR); April 1-5, 2017; Washington, DC. Abstract CT117. Indoximod plus Provenge (sipuleucel-T) Vaccine 6 Randomized, Double Blind, Placebo Controlled Phase 2 Study Abstract 3066 Jha et al.